semaglutide alzheimer trial in early-stage Alzheimer's Disease Semaglutide Misses Mark for Alzheimer

In a phase 2b trial, tirzepatide treatment was associated in a dose-dependent manner with decreased levels of apolipoprotein (apo) B, apoC-III, large triglyceride-rich lipoprotein particles, and small low-density lipoprotein particles, suggesting a shift towards a less atherogenic lipoprotein profile [77]

the gel purified digested His6-AV-Ubiquitin- semapeptide (nucleotide sequence) encoding gene PCR product was ligated into Ndel and Xhol sites of pET24 plasmid vector using Quick ligation kit (NEB)

The selection window for initiation of the index drug was from January 1, 2018 to 720 days before the end of the study

Fotiou, K., Hofmann, M., Kaufmann, R